ESMO 2023 | What is the optimal time to surgery post-neoadjuvant CRT for esophageal cancer?

Magnus Nilsson, MD, PhD, FACS, Karolinska University Hospital, Stockholm, Sweden, discusses findings from the NeoRes II trial, which assessed standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy (CRT) in patients with esophageal cancer. Whilst there was no statistical difference, patients with delayed surgery tended to have worse overall survival. Therefore, caution is advised for delaying surgery after six weeks. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.